S&P Futures
4,226.75 +17.00 (+0.40%) Dow Futures
33,419.00 +115.00 (+0.35%) Nasdaq Futures
13,375.00 +63.75 (+0.48%) Russell 2000 Futures
1,985.70 +9.40 (+0.48%) Crude Oil
94.18 -0.16 (-0.17%) Gold
1,803.60 -3.60 (-0.20%)
Nabriva Therapeutics plc (NBRV)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.1900 |
| Open | 0.1952 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 900 |
| Day's Range | 0.1900 - 0.2144 |
| 52 Week Range | 0.1560 - 1.4000 |
| Volume | |
| Avg. Volume | 806,093 |
| Market Cap | 10.975M |
| Beta (5Y Monthly) | 1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6220 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.00 |
- GlobeNewswire
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the completion of patient enrollment in its Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA® (lefamulin) in adult patients with cystic fib
- GlobeNewswire
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2022 and provided a corporate upda
- GlobeNewswire
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022. Nabriva’s management will host a conference call at 4:3
